hVIVO plc (LON:HVO - Get Free Report) shares rose 23.6% on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.75 ($0.15). Approximately 35,585,328 shares were traded during trading, an increase of 853% from the average daily volume of 3,733,846 shares. The stock had previously closed at GBX 8.70 ($0.12).
Analyst Ratings Changes
Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a report on Friday.
Check Out Our Latest Analysis on HVO
hVIVO Stock Down 2.8%
The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company's fifty day moving average price is GBX 16.08 and its 200-day moving average price is GBX 17.93. The stock has a market capitalization of £73.59 million, a PE ratio of 4.29 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current year.
Insider Activity at hVIVO
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($703,774.26). 14.03% of the stock is currently owned by insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
